Frontiers in Pharmacology最新文献

{"title":"Editorial: Mendelian randomization and cardiovascular remodeling.","authors":"Jianxin Qiang, Jia Yang, Yanwu Liu, Ji Zhang, Hao Sun, Lijuan Li, Duo Wang, Yanping Liu, Panpan Hao","doi":"10.3389/fphar.2025.1593325","DOIUrl":"https://doi.org/10.3389/fphar.2025.1593325","url":null,"abstract":"","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1593325"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Pain and pain-related neuropsychiatric disorders: from mechanistic insights to innovative therapeutic strategies.","authors":"Rosmara Infantino, Fabio Turco, Francesca Guida, Álvaro Llorente-Berzal","doi":"10.3389/fphar.2025.1593890","DOIUrl":"https://doi.org/10.3389/fphar.2025.1593890","url":null,"abstract":"","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1593890"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multigenetic pharmacogenomics-guided treatment shows greater improvements on motor symptoms compared to usual therapy in Parkinson's disease: a small real-word prospective cohort study.","authors":"Yifan Li, Mao Li, Miao Wang, Jiarui Yao, Fengzhu Li, Siyu Chen, Xi Yin, Zhongbao Gao","doi":"10.3389/fphar.2025.1502379","DOIUrl":"https://doi.org/10.3389/fphar.2025.1502379","url":null,"abstract":"<p><strong>Background: </strong>Dopamine replacement therapy is a cornerstone of Parkinson's disease treatment. In clinical practice, there is considerable variability in patients' responses, tolerability, and safety regarding anti-parkinsonian medications, which is largely influenced by genetic polymorphisms in pharmacokinetic and pharmacodynamic genes. However, the application of multigenetic pharmacogenomics-guided treatment (MPGT) to optimize therapeutic outcomes in Parkinson's disease (PD) remains under-explored. In this study, we conducted a prospective cohort investigation to evaluate the potential benefits of MPGT on motor symptoms in PD patients.</p><p><strong>Methods: </strong>A total of 28 patients with PD were followed for 4 weeks. Among them, 22 patients underwent multigenetic pharmacogenomic testing, with 13 receiving treatments based on the test results (MPGT group). The remaining 15 received standard care (TAU group). Baseline characteristics, as well as changes in Unified Parkinson's Disease Rating Scale (UPDRS) III scores and sub-scores, were compared between the two groups. Associations between various single nucleotide polymorphisms (SNPs) and treatment outcomes were analyzed using generalized linear models.</p><p><strong>Results: </strong>At the 4-week follow-up, the MPGT group showed significantly greater reductions in UPDRS III total scores (p < 0.05) and limb sub-scores (p < 0.01) compared to the TAU group. These differences remained significant after adjusting for increases in levodopa equivalent daily dose (<i>p =</i> 0.011 and <i>p =</i> 0.002, respectively) and piribedil use (<i>p =</i> 0.006 and <i>p =</i> 0.004, respectively). Patients homozygous for the major allele of rs4984241 (AA vs. AG+GG, <i>p =</i> 0.003), rs4680 (GG vs. GA+AA, <i>p =</i> 0.013), rs1076560/rs2283265 (CC vs. AC+AA, <i>p =</i> 0.039) and rs622342 (AA vs. AC, <i>p =</i> 0.043) showed greater improvement in total UPDRS III, postural instability and gait difficulty (PIGD), rigidity and tremor scores, respectively, compared to those carrying at least one minor allele.</p><p><strong>Conclusion: </strong>MGPT demonstrates significant potential as a valuable tool for personalized treatment in PD patients. Additionally, we identified several SNPs associated with the responsiveness to chronic administration of multiple anti-parkinsonian drugs. However, to confirm these findings, well-designed studies with larger, well-characterized samples are necessary.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1502379"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An active ingredient from the combination of Corydalis Rhizoma and Paeoniae Radix Alba relieves chronic compression injury-induced pain in rats by ameliorating AR/Mboat2-mediated ferroptosis in spinal cord neurons.","authors":"Ze-Ming Wang, Xiao-Hong Wei, Gui-Yang Xia, Lin-Nan Zhou, Jin-Yu Li, Sheng Lin","doi":"10.3389/fphar.2025.1558916","DOIUrl":"https://doi.org/10.3389/fphar.2025.1558916","url":null,"abstract":"<p><strong>Introduction: </strong>A combination of Corydalis Rhizoma (the dried tuber of <i>Corydalis yanhusuo</i> W.T. Wang) and Paeoniae Radix Alba (the root of <i>Paeonia lactiflora</i> Pall.) has been traditionally employed for analgesia. However, the underlying pharmacological mechanisms have not been clarified. The aim of the present study was to investigate the anti-inflammatory and analgesic effects of YB60, the 60% ethanol elution fraction derived from the combination of Corydalis Rhizoma and Paeoniae Radix Alba, and the explore the underlying mechanism.</p><p><strong>Methods: </strong>Lipopolysaccharide-induced cellular inflammation model and chronic compression injury (CCI) rat model were used to study the anti-inflammatory and analgesic effects of YB60. Proteomics and molecular biology experiments were applied to explore the potential analgesic mechanism of YB60.</p><p><strong>Results: </strong>The results demonstrated that YB60 significantly decreased inflammatory cytokine levels both in cellular models and rat serum, while concurrently elevating pain thresholds in CCI rats. Proteomic analysis indicated that YB60 could upregulate the expression of Membrane Bound O-Acyltransferase Domain Containing 2 (Mboat2), a newly confirmed marker of ferroptosis. Furthermore, YB60 prevented ferroptosis in the spinal cords of CCI rats. Western blotting and immunofluorescent dual staining further revealed that YB60 increased the expression of Mboat2 and its upstream signaling molecule Androgen receptor (AR). Results in PC12 cells <i>in vitro</i> showed that YB60 reversed the downregulation of AR and Mboat2, and ameliorated ferroptosis induced by Erastin, while knockdown of AR eliminated the above effects of YB60.</p><p><strong>Conclusion: </strong>These findings indicated that YB60 exerted its analgesic effect by inhibiting ferroptosis in spinal cord neurons via modulation of the AR/Mboat2 pathway.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1558916"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis.","authors":"Bashaier Al-Zaid, Suleiman Al-Sabah","doi":"10.3389/fphar.2025.1528295","DOIUrl":"https://doi.org/10.3389/fphar.2025.1528295","url":null,"abstract":"<p><p><b>Introduction:</b> Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of metabolism and mediate the incretin effect. This glucose-dependent potentiation of insulin secretion is severely impaired in patients with type-2 diabetes mellitus. While pharmacological doses of GLP-1 can overcome this impairment, the same is not true for GIP. The reasons for this are unclear. However, differences in the signalling profiles of the GLP-1 and GIP receptors (GLP-1R and GIPR) may contribute. GLP-1R and GIPR are closely related G protein-coupled receptors but differ in their ability to recruit arrestin, GIPR being relatively poorer. Furthermore, these receptors have been reported to utilize different mechanisms to undergo agonist-induced internalization. <b>Methods:</b> This study aimed to identify the role of the C-terminal region of the two receptors in their differing signalling behaviour using chimeric receptors where the C-terminal tail of one receptor was replaced with that of the other. <b>Results:</b> Replacement of the C-terminal tail had only limited effects on G protein and arrestin recruitment to either receptor. GIP-stimulated internalisation of GIPR occurred at a significantly (<i>P</i> < 0.001) slower rate than GLP-1-stimulated internalisation of GLP-1R. Replacement of the C-terminal tail of GIPR with that of GLP-1R significantly (<i>P</i> < 0.05) increased the internalization rate but not to the rate of wild-type GLP-1R. The reciprocal substitution significantly (<i>P</i> < 0.005) decreased internalization rate. <b>Conclusion:</b> These data show that the C-terminal region of GLP-1R and GIPR is not the critical determinant of their differing ability to recruit arrestin but modulates receptor endocytosis.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1528295"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine.","authors":"Ziyi Zhu, Jiayang Shen, Paul Chi-Lui Ho, Ya Hu, Zhaowu Ma, Lingzhi Wang","doi":"10.3389/fphar.2025.1563198","DOIUrl":"https://doi.org/10.3389/fphar.2025.1563198","url":null,"abstract":"<p><p>The persistently high mortality rates associated with cancer underscore the imperative need for innovative, efficacious, and safer therapeutic agents, as well as a more nuanced understanding of tumor biology. Patient-derived organoids (PDOs) have emerged as innovative preclinical models with significant translational potential, capable of accurately recapitulating the structural, functional, and heterogeneous characteristics of primary tumors. When integrated with cutting-edge genomic tools such as CRISPR, PDOs provide a powerful platform for identifying cancer driver genes and novel therapeutic targets. This comprehensive review delves into recent advancements in CRISPR-mediated functional screens leveraging PDOs across diverse cancer types, highlighting their pivotal role in high-throughput functional genomics and tumor microenvironment (TME) modeling. Furthermore, this review highlights the synergistic potential of integrating PDOs with CRISPR screens in cancer immunotherapy, focusing on uncovering immune evasion mechanisms and improving the efficacy of immunotherapeutic approaches. Together, these cutting-edge technologies offer significant promise for advancing precision oncology.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1563198"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Lycorine displays potent antitumor efficacy in colon carcinoma by targeting STAT3.","authors":"","doi":"10.3389/fphar.2025.1596508","DOIUrl":"https://doi.org/10.3389/fphar.2025.1596508","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fphar.2018.00881.].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1596508"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenylethyl isothiocyanate mitigates drug-induced liver injury in mice by inhibiting hepatocyte pyroptosis through the NLRP3-caspase-1-GSDMD pathway.","authors":"Ning An, Xiaoru Wang, Jia Qin, Meng Cheng, Mei Bai, Jingcai Cheng, Qiang Xu, Xuefeng Wu","doi":"10.3389/fphar.2025.1539934","DOIUrl":"https://doi.org/10.3389/fphar.2025.1539934","url":null,"abstract":"<p><p><b>Introduction:</b> Drug-induced liver injury (DILI) represents a distinct form of hepatic damage resulting from exposure to pharmacological agents. The pathological mechanisms underlying DILI are multifaceted and remain incompletely elucidated. However, emerging evidence suggests that cell pyroptosis, a form of programmed cell death associated with inflammation, may serve as a common mechanistic pathway in DILI pathogenesis. <b>Methods:</b> To investigate the role of pyroptosis in DILI, we established a murine model of DILI using triptolide and evaluated the therapeutic potential of phenethyl isothiocyanate (PEITC), a naturally occurring compound, in mitigating liver injury through the modulation of hepatocyte pyroptosis. Mice were administered PEITC at doses ranging from 5 to 20 mg/kg. Cytokine expression was measured using quantitative polymerase chain reaction or biochemical indicator analyzer. Cell signalings were assayed by western blot and immunohistochemistry. The AML12 hepacytes were cultured to investigate the <i>in vitro</i> effects. <b>Results:</b> PEITC treatment markedly attenuated hepatic tissue damage, restored normal liver architecture, and significantly reduced serum levels of transaminases (AST and ALT), while normalizing hepatic metabolic function. These protective effects were mechanistically linked to the suppression of hepatocyte pyroptosis, as PEITC effectively reversed the upregulation of the NLRP3 inflammasome, Caspase-1 cleavage, and Gasdermin D (GSDMD) in triptolide-exposed livers. <i>In vitro</i> studies using cultured hepatocytes further demonstrated that PEITC inhibited the expression and activation of NLRP3, Caspase-1, GSDMD, and other key proteins involved in the pyroptosis pathway. Ultrastructural analysis via electron microscopy corroborated these findings, revealing that PEITC prevented pyroptosis-induced membrane pore formation in hepatocytes. <b>Conclusions:</b> PEITC exerts hepatoprotective effects against DILI by targeting the pyroptosis pathway, thereby highlighting its potential as a novel therapeutic strategy for liver injuries. Our results further implicate cell pyroptosis as a novel target for the attenuation of DILI.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1539934"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Debates in experimental pharmacology and drug discovery 2023: innovative approaches to chronic kidney disease drug discovery, identification of targets and safety assessment.","authors":"Md Abdul Hye Khan, Omar Z Ameer, Samaneh Goorani, Ibrahim M Salman","doi":"10.3389/fphar.2025.1588367","DOIUrl":"https://doi.org/10.3389/fphar.2025.1588367","url":null,"abstract":"","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1588367"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focus on P2X7R in microglia: its mechanism of action and therapeutic prospects in various neuropathic pain models.","authors":"Kai Zhang, Rui Ran, Cheng-Jun Zhang, Linna Wang, Hai-Hong Zhang","doi":"10.3389/fphar.2025.1555732","DOIUrl":"https://doi.org/10.3389/fphar.2025.1555732","url":null,"abstract":"<p><p>Neuropathic pain (NP) is a common symptom of many diseases and is caused by direct or indirect damage to the nervous system. Tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors are typical drugs used in clinical practice to suppress pain. However, these drugs have drawbacks, including a short duration of action, a limited analgesic effect, and possible dependence and side effects. Therefore, developing more effective NP treatment strategies has become a priority in medical research and has attracted much research attention. P2X7 receptor (P2X7R) is a non-selective cation channel activated by adenosine triphosphate and is mainly expressed in microglia in the central nervous system. Microglial P2X7R plays an important role in pain regulation, suggesting that it could be a potential target for drug development. This review comprehensively and objectively discussed the latest research progress of P2X7R, including its structural characteristics, functional properties, relationship with microglial activation and polarization, mechanism of action, and potential therapeutic strategies in multiple NP models. This study aimed to provide in-depth insights into the association between P2X7R and NP and explore the mechanism of action of P2X7R in the pathological process of NP and the translational potential and clinical application prospects of P2X7R antagonists in pain treatment, providing a scientific basis for the precise treatment of NP.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1555732"},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}